We are live on ! Find out more
REVB icon

Revelation Biosciences

5 hedge funds and large institutions have $759K invested in Revelation Biosciences in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.02%0% (-0.02%)

28% less capital invested

Capital invested by funds: $1.05M → $759K (-$289K)

29% less funds holding

Funds holding: 75 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
Closed
4
Calls
Puts
Net Calls
Net Calls Change

REVB Hedge Fund Activity: Q2 2023 in Review

5 institutional investors reported a position in Revelation Biosciences (REVB) for Q2 2023, worth a combined $759K — down 28% from $1.05M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of REVB and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Sabby Management, adding an estimated $188K. The largest seller was Anson Funds Management, exiting entirely with an estimated $278K sold.

  • 5 institutional investors held Revelation Biosciences (REVB) as of Q2 2023, down from 7 in Q1 2023.
  • Funds reported $759K of Revelation Biosciences stock for Q2 2023, down 28% quarter-over-quarter.
  • 2 funds opened new Revelation Biosciences positions in Q2 2023 and 4 closed out, a net change of -2 holders.
  • The largest Revelation Biosciences buyer in Q2 2023 was Sabby Management, an estimated $188K added.
  • The largest Revelation Biosciences seller in Q2 2023 was Anson Funds Management, an estimated $278K sold.

Based on aggregated 13F filings for Q2 2023.